When cancer is diagnosed, finding treatment options is the top priority
OncoTarget® Series is our comprehensive genomic profiling solution to identify targeted immunotherapies for advanced cancers–solid tumors or leukemias.
Your confidence is found within OncoTarget’s
multi-technology platform
multi-technology platform
MSI and Single Mutations
Sample Collection
Sample Processing
Results
GoPath® Diagnostics Launches FDA-Cleared CGP Test under OncoTarget® 500
OncoTarget®500 genomic profiling identifies tumor-based somatic mutations with high accuracy and sensitivity – single nucleotide variants (SNVs), small insertions and deletions, amplifications, translocations, microsatellite instability (MSI) and tumor mutation burden (TMB). OncoTarget® 500 is designed to be used by qualified healthcare professionals in accordance with professional guidelines in oncology for previously diagnosed cancer patients.
